Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Summary

Silo Pharma, Inc. has commenced a pharmacokinetic and tolerability study for its ketamine-based injectable implant, SP-26, aimed at treating chronic pain and fibromyalgia. Conducted in partnership with AmplifyBio, this study will evaluate the implant’s pharmacokinetics in a minipig model over three weeks. This milestone is part of efforts to advance SP-26 towards potential FDA approval.

Impact Analysis

This event is classified at the company level as it specifically involves Silo Pharma’s strategic move to further develop SP-26. The initiation of this study marks a crucial step in the drug development process, potentially increasing investor confidence and impacting Silo Pharma’s stock positively. The partnership with AmplifyBio and prior collaborations with Kymanox highlight Silo’s strategic alliances in progressing their drug pipeline.Benzinga+ 2 First-order effects include potential stock price movements due to increased interest in Silo Pharma’s research advancements. Second-order effects could involve shifts in the competitive landscape of the biopharmaceutical industry, particularly in treatments for chronic pain and fibromyalgia. Investment opportunities may arise from potential stock appreciation of Silo Pharma, contingent on the study’s success and subsequent FDA approval progress.